BOAN BIOTECH's stock price plummeted 5.15% during intraday trading on Tuesday, following the release of its annual financial results.
The sharp decline came after the company reported its full-year results for the period ending December 31, 2025. While revenue increased by 8.06% year-on-year to approximately RMB 785 million, profit attributable to owners narrowed dramatically by 90.24% to RMB 7.144 million. The significant profit contraction, despite revenue growth, likely triggered the negative investor sentiment and selling pressure.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments